Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 6,313 shares, a decrease of 46.2% from the August 15th total of 11,736 shares. Based on an average daily trading volume, of 2,072 shares, the short-interest ratio is presently 3.0 days.
Oculis Stock Performance
OCSAW remained flat at $3.14 during trading on Thursday. 5,018 shares of the company’s stock traded hands, compared to its average volume of 5,417. Oculis has a 12 month low of $2.71 and a 12 month high of $22.64. The business has a fifty day moving average of $4.48 and a 200-day moving average of $9.95.
About Oculis
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Further Reading
- Five stocks we like better than Oculis
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
